ArticleFrontiers in aging2026
Impact of comorbidities in patients with erosive hand osteoarthritis (EHOA), a monocentric study.
Article in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Erosive hand osteoarthritis (EHOA) is a severe and rapidly progressing form of osteoarthritis that has been linked to systemic comorbidities (i.e., metabolic bone and cardiovascular diseases). The object of this study is to retrospectively evaluate the impact of comorbidities (i.e., osteoporosis, diabetes and overweight) on the clinical course and radiographic findings in a cohort of EHOA patients. Design: This is a retrospective cross-sectional study. Patients underwent clinical assessments and completed the VAS scale, the AUSCAN and DREISER questionnaires. Metabolic, cardiovascular, and bone health data were collected. Radiographic features-osteophytes, joint space narrowing, malalignment, erosions, sclerosis, and subchondral cysts-were evaluated using the Altman system. Comorbidities were assessed using the Charlson Comorbidity Index, whereas metabolic syndrome, diabetes, and osteoporosis were defined according to the ATP III and WHO criteria. Statistical analysis was conducted via Spearman's correlation, using GraphPad Prism 9.1.0, with significance set at p < 0.05. Results: Eighty-seven patients (88.5% female, mean age 63.17 ± 8.85) were included. Among comorbidities, 76.8% had at least one risk factor; BMI correlated with joint space narrowing (r = 0.22, p = 0.04). Severity of femoral and lumbar osteoporosis correlated with AUSCAN and DREISER scores; FRAX scores significantly correlated with several radiographic features of EHOA; VAS correlated with swollen and painful joint count, with AUSCAN and DREISER scores and with osteophytosis. Disease duration correlated with overall radiographic damage. Conclusion: Cardiovascular and metabolic bone comorbidities, especially overweight and osteoporosis, appear to be associated with higher pain burden, functional impairment, and greater structural damage in EHOA patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.